Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

AllAAOIABUSABVXACADACRVADMAAGIOALMSALMUALTSAPGEARTVASXAUPHAVAVAVPTAXTIBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTMXCTRIDKNGDUOLFLUTGCTGLWGOOGGPCRHALOHCAHIMSHOODHWMIDYAIRENIVVDKALAKALVKRYSLENZLEVILITELQDALRMRLULULUNRMDGLMESOMIRMMOHMPWRMTCHMUMVSTNBISNKENRIXNUENVAXNXPIOKUROLMAONCONTOORKAOSCRPDFSPHATPOETPRLDPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHATTMIUNHVEONVORWVEXFORZBIOZLABZYME
Halozyme's stock drop is misunderstood. The "institutional selling" is an accounting change, not a real exit. Insider sales are pre-planned for taxes. The CEO's new pay package requires the stock to hit $115 to fully vest, showing strong board confidence.

The Disconnect in HALO: Why the Crowd is Misreading Halozyme's $61 Bottom

2026-03-28BullishStrongChange from report: +76.8%1M: +2.8%3M: +24.2%

Halozyme's stock drop is misunderstood. The "institutional selling" is an accounting change, not a real exit. Insider sales are pre-planned for taxes. The CEO's new pay package requires the stock to hit $115 to fully vest, showing strong board confidence.